Salla Kati, Restitutti Flavia, Vainionpää Mari, Junnila Jouni, Honkavaara Juhana, Kuusela Erja, Raekallio Marja, Vainio Outi
Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
Vet Anaesth Analg. 2014 Nov;41(6):567-74. doi: 10.1111/vaa.12158. Epub 2014 Mar 28.
To compare the cardiopulmonary effects of intravenous (IV) and intramuscular (IM) medetomidine and butorphanol with or without MK-467.
Prospective, randomized experimental cross-over.
Eight purpose-bred beagles (two females, six males), 3-4 years old and weighing 14.5 ±1.6 kg (mean ± SD).
All dogs received four different treatments as follows: medetomidine 20 μg kg(-1) and butorphanol tartrate 0.1 mg kg(-1) IV and IM (MB), and MB combined with MK-467,500 μg kg(-1) (MBMK) IV and IM. Heart rate (HR), arterial blood pressures (SAP, MAP, DAP), central venous pressure (CVP), cardiac output, respiratory rate (fR ), rectal temperature (RT) were measured and arterial blood samples were obtained for gas analysis at baseline and at 3, 10, 20, 30, 45 and 60 minutes after drug administration. The cardiac index (CI), systemic vascular resistance index (SVRI) and oxygen delivery index (DO2 I) were calculated. After the follow-up period atipamezole 50 μg kg(-1) IM was given to reverse sedation.
HR, CI and DO2 I were significantly higher with MBMK after both IV and IM administration. Similarly, SAP, MAP, DAP, CVP, SVRI and RT were significantly lower after MBMK than with MB. There were no differences in fR between treatments, but arterial partial pressure of oxygen decreased transiently after all treatments. Recoveries were uneventful following atipamezole administration after all treatments.
MK-467 attenuated the cardiovascular effects of a medetomidine-butorphanol combination after IV and IM administration.
比较静脉注射（IV）和肌肉注射（IM）美托咪定与布托啡诺联用或不联用MK-467时对心肺的影响。
前瞻性随机实验交叉研究。
8只专门培育的比格犬（2只雌性，6只雄性），3 - 4岁，体重14.5±1.6千克（均值±标准差）。
所有犬接受如下四种不同治疗：静脉注射和肌肉注射美托咪定20μg/kg(-1)与酒石酸布托啡诺0.1mg/kg(-1)（MB），以及静脉注射和肌肉注射MB联合MK-467 500μg/kg(-1)（MBMK）。在基线以及给药后3、10、20、30、45和60分钟测量心率（HR）、动脉血压（收缩压、平均动脉压、舒张压）、中心静脉压（CVP）、心输出量、呼吸频率（fR）、直肠温度（RT），并采集动脉血样进行气体分析。计算心脏指数（CI）、全身血管阻力指数（SVRI）和氧输送指数（DO2I）。随访期结束后，肌肉注射阿替美唑50μg/kg(-1)以逆转镇静作用。
静脉注射和肌肉注射MBMK后，HR、CI和DO2I均显著更高。同样，MBMK后收缩压、平均动脉压、舒张压、中心静脉压、SVRI和RT均显著低于MB。各治疗组间fR无差异，但所有治疗后动脉血氧分压均短暂下降。所有治疗后给予阿替美唑后恢复顺利。
MK-467减弱了静脉注射和肌肉注射美托咪定 - 布托啡诺组合后的心血管效应。
